Kesler Norman & Wride LLC Raises Holdings in Eli Lilly and Company (NYSE:LLY)

Kesler Norman & Wride LLC increased its position in Eli Lilly and Company (NYSE:LLY) by 10.2% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 4,014 shares of the company’s stock after buying an additional 372 shares during the period. Kesler Norman & Wride LLC’s holdings in Eli Lilly and Company were worth $3,556,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in LLY. Regal Investment Advisors LLC raised its position in Eli Lilly and Company by 41.3% during the fourth quarter. Regal Investment Advisors LLC now owns 4,808 shares of the company’s stock valued at $2,803,000 after purchasing an additional 1,405 shares during the period. VitalStone Financial LLC lifted its position in Eli Lilly and Company by 35.5% in the fourth quarter. VitalStone Financial LLC now owns 1,249 shares of the company’s stock worth $728,000 after buying an additional 327 shares during the last quarter. Advanced Portfolio Management LLC purchased a new position in Eli Lilly and Company during the fourth quarter worth $1,736,000. Visionary Wealth Advisors increased its position in Eli Lilly and Company by 2.7% during the fourth quarter. Visionary Wealth Advisors now owns 1,872 shares of the company’s stock valued at $1,091,000 after acquiring an additional 49 shares during the last quarter. Finally, Bridgewater Associates LP lifted its holdings in shares of Eli Lilly and Company by 412.5% in the 4th quarter. Bridgewater Associates LP now owns 317,586 shares of the company’s stock worth $185,127,000 after acquiring an additional 255,619 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $898.40 on Tuesday. The business has a fifty day moving average of $900.13 and a 200 day moving average of $848.40. Eli Lilly and Company has a 1 year low of $547.61 and a 1 year high of $972.53. The company has a debt-to-equity ratio of 1.74, a current ratio of 1.11 and a quick ratio of 0.87. The firm has a market capitalization of $853.84 billion, a price-to-earnings ratio of 132.31, a price-to-earnings-growth ratio of 2.78 and a beta of 0.42.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. The business had revenue of $11.30 billion for the quarter, compared to analyst estimates of $9.83 billion. As a group, research analysts expect that Eli Lilly and Company will post 16.49 earnings per share for the current year.

Insider Buying and Selling at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 210,000 shares of the stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the sale, the insider now owns 96,943,810 shares in the company, valued at $91,109,731,514.20. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 0.13% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on LLY shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Wells Fargo & Company lifted their price target on shares of Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Berenberg Bank increased their price target on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research report on Wednesday, August 14th. BMO Capital Markets raised their price target on Eli Lilly and Company from $1,001.00 to $1,101.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. Finally, Guggenheim upped their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research note on Friday, August 16th. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $977.35.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.